NO20083240L - Sammensetninger og fremgangsmater for forebygging og behandling av kakeksia - Google Patents

Sammensetninger og fremgangsmater for forebygging og behandling av kakeksia

Info

Publication number
NO20083240L
NO20083240L NO20083240A NO20083240A NO20083240L NO 20083240 L NO20083240 L NO 20083240L NO 20083240 A NO20083240 A NO 20083240A NO 20083240 A NO20083240 A NO 20083240A NO 20083240 L NO20083240 L NO 20083240L
Authority
NO
Norway
Prior art keywords
compositions
methods
treatment
swine
cachexia
Prior art date
Application number
NO20083240A
Other languages
English (en)
Norwegian (no)
Inventor
Richard Kenley
Jonas Ekblom
Mikhail Denissenko
Original Assignee
Anaborex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaborex Inc filed Critical Anaborex Inc
Publication of NO20083240L publication Critical patent/NO20083240L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NO20083240A 2005-12-22 2008-07-22 Sammensetninger og fremgangsmater for forebygging og behandling av kakeksia NO20083240L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75311805P 2005-12-22 2005-12-22
US77275206P 2006-02-13 2006-02-13
PCT/IB2006/004315 WO2008093148A2 (fr) 2005-12-22 2006-12-20 Compositions et procédés pour la prévention et le traitement de la cachexie

Publications (1)

Publication Number Publication Date
NO20083240L true NO20083240L (no) 2008-09-22

Family

ID=38194678

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083240A NO20083240L (no) 2005-12-22 2008-07-22 Sammensetninger og fremgangsmater for forebygging og behandling av kakeksia

Country Status (6)

Country Link
US (1) US8080528B2 (fr)
EP (1) EP1991270A4 (fr)
JP (1) JP2009526087A (fr)
MX (1) MX2008007790A (fr)
NO (1) NO20083240L (fr)
WO (1) WO2008093148A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7417038B1 (en) 1998-10-15 2008-08-26 Imperial Innovations Limited Methods of treating cachexia
GB0624282D0 (en) 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
AU2008240379B2 (en) * 2007-04-24 2012-10-04 Acacia Pharma Limited Drug combination of beta 2 agonist and a progestin for the treatment of muscle loss
WO2008144763A2 (fr) 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Anticorps anti-il-6 et leur utilisation
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US20090221518A1 (en) * 2007-11-18 2009-09-03 Anaborex, Inc. Compositions and Methods for Treatment of Exudative Serous Effusion
WO2009120836A1 (fr) * 2008-03-26 2009-10-01 Neurosigma, Inc. Procédés d’identification et de ciblage de régions du cerveau autonome
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
SG171804A1 (en) * 2008-11-25 2011-07-28 Alder Biopharmaceuticals Inc Antibodies to il-6 and use thereof
WO2011066369A2 (fr) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonistes de l'il-6 destinés à faire augmenter l'albumine et/ou à faire baisser la crp
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
WO2012009542A2 (fr) * 2010-07-14 2012-01-19 Kansas State University Research Foundation Procédés de soulagement de la douleur chronique et d'amélioration de la performance du bétail subissant un écornage ou une castration
ES2847891T3 (es) 2010-11-23 2021-08-04 Vitaeris Inc Anticuerpos anti-IL-6 para el tratamiento de la mucositis oral
KR20210075191A (ko) * 2012-03-28 2021-06-22 애피바디 에이비 경구투여
WO2020018554A1 (fr) * 2018-07-17 2020-01-23 The Regents Of The University Of California Méthodes de traitement d'une maladie rénale

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859782A (en) * 1986-06-26 1989-08-22 Harbor Branch Oceanographic Institution, Inc. Misakinolide compositions and their derivatives
ATE149089T1 (de) 1987-09-15 1997-03-15 Rowett Research Inst Anwendungsgebiete von beta-adrenergenen agonisten
HUT50044A (en) * 1988-04-12 1989-12-28 Bristol Myers Co Process for producing pharmaceutical composition comprising megestrol acetate as active ingredient
US5252564A (en) * 1991-03-29 1993-10-12 The United States Of America As Represented By The Secretary Of Agriculture Method to decrease cortisol secretion by feeding melengesterol acetate
EP0771205A2 (fr) * 1994-06-28 1997-05-07 Dr. Zerle Gmbh Nouvelles utilisations cliniques de polyenes-macrolides
US5750493A (en) * 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
US6706892B1 (en) * 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US7211568B2 (en) * 2003-12-18 2007-05-01 Kosan Biosciences Incorporated 9-Desoxoerythromycin compounds as prokinetic agents
WO2008004224A2 (fr) 2006-07-03 2008-01-10 Arie Levine Compositions synergiques pour la maladie de crohn et des troubles gastro-intestinaux inflammatoires

Also Published As

Publication number Publication date
EP1991270A2 (fr) 2008-11-19
JP2009526087A (ja) 2009-07-16
WO2008093148A2 (fr) 2008-08-07
US20070149465A1 (en) 2007-06-28
US8080528B2 (en) 2011-12-20
EP1991270A4 (fr) 2009-12-02
WO2008093148A3 (fr) 2009-04-16
MX2008007790A (es) 2009-03-04

Similar Documents

Publication Publication Date Title
NO20083240L (no) Sammensetninger og fremgangsmater for forebygging og behandling av kakeksia
WO2007095497A3 (fr) Compositions et méthodes pour prévenir et traiter la cachexie
NO20062300L (no) Fremgangsmater og reagenser for behandling av inflammatoriske forstyrelser
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
ECSP17000643A (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol.
TW200631578A (en) Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
ATE510538T1 (de) Zusammensetzungen und verfahren für nervenschutz
EA200970542A1 (ru) ИНГИБИТОРЫ ДЕЙСТВИЯ Akt
ES2571730T3 (es) Composiciones farmacéuticas que comprenden droxidopa
BRPI0413326A (pt) métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel
MX2007006066A (es) Inhibidores de jnk para el tratamiento de lesiones del snc.
GT200600160A (es) Tratamiento del dolor
CL2008001782A1 (es) Uso de una composicion que comprende un compuesto derivado de heterociclo para tratar o prevenir la perdida de flujo intestinal; composicion que comprende dicho compusto; y kit que comprende la composicion.
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
ATE522500T1 (de) Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür
NO20073104L (no) Anvendelse av en 5-HT6 agonist for behandling og forebygging av neurodegenerative forstyrrelser
EA200901062A1 (ru) Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств
EA200970338A2 (ru) Агонисты рецептора еро человека, композиции, способы и применение для предотвращения или лечения состояний, связанных с интолерантностью к глюкозе
NO20092230L (no) Azabicykliske heterocykler som cannabinoid reseptor modulatorer
EA202190678A1 (ru) Вибегрон для лечения симптомов гиперактивного мочевого пузыря
EA201990365A1 (ru) Лечение и предотвращение расстройств сна
EA200800343A1 (ru) Ингибиторы jnk для лечения эндометриоза
UY29237A1 (es) Metodos detratamiento y prevencion

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application